Recently, Guangzhou Hanfang National Engineering Research Center started cooperation with Sun-Yet-sen University (SYSU) to conduct research on the curative effects of GPHL’s Ling Zhi Bao Zi You which is a traditional Chinese medicine (TCM) made from Ganoderma Spore Lipids.

The research will consider the medicine’s effects on extending cancer patients’ life expectancy, chemotherapy tolerance and etc., aiming to analyze its functional components and prove its effects of lifespan extension, immunity enhancement, toxicity reduction, efficacy enhancement and synergistic interaction, and make breakthroughs in cancer therapy.

According to Prof. Wang Qin, deputy director of SYSU National New Drug Preclinical Pharmacodynamic Evaluation Technology Platform, the cooperation is supported by national fundings for “significant new drugs development”. The findings of preliminary study were in line with expectations, and the exploration of Ganoderma spore lipids’ effects on tolerance enhance and lifespan extension were inspirational. It was expected to achieve more satisfactory results.

Guangzhou Hanfang Pharmaceutical Co., Ltd. (Guangzhou Hanfang) is a subsidiary of GPHL. As the only engineering research center for extraction and separation of TCM approved by the National Development and Reform Commission, the pharma also serves as the national TCM  R&D platform jointly supported by multiple centers, key laboratories and research institutes. It sustains a leading position nationwide, and it is a pioneering in the TCM modernization.

With years of research and practice, Ganoderma Spore Lipids, a new-type TCM developed with Guangzhou Hanfang’s technology, has obtained 9 national patents for invention.